Hera


9M 26: Steady delivery, leverage at the plan ceiling

11/11/26 -"Hera posted a solid 9M 26, with adjusted EBITDA up 6.9% to €1,036.7m and adjusted net profit up 16.5% to €296.7m. Q3 carried no special items, and implied Q3 adjusted EBITDA growth eased to +5.4% ..."

Pages
57
Language
English
Published on
11/11/26
You may also be interested by these reports :
11/11/26
Hera posted a solid 9M 26, with adjusted EBITDA up 6.9% to €1,036.7m and adjusted net profit up 16.5% to €296.7m. Q3 carried no special items, and ...

11/11/26
RWE posted a strong 9M 26, with adj. EBITDA up 35% yoy to €4.6bn and adj. EPS up 42% to €2.52, c.85% of the FY guidance mid-point. Supply & Trading ...

11/11/26
Another guidance-confirming quarter: adjusted EBITDA was flat at €7.1bn on a restated basis, adjusted net income rose 4%, and FY2026 and FY2030 ...

09/11/26
We have raised our 2026 estimates to reflect a stronger-than-expected 9M26 and the upgraded guidance, now c.€5.4bn of recurring EBITDA and ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO